Assessment  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
the  ||| S:14 E:18 ||| DT
internal  ||| S:18 E:27 ||| JJ
structure  ||| S:27 E:37 ||| NN
of  ||| S:37 E:40 ||| IN
GOLD  ||| S:40 E:45 ||| NNP
2011  ||| S:45 E:50 ||| CD
system  ||| S:50 E:57 ||| NN
Global  ||| S:57 E:64 ||| NNP
Initiative  ||| S:64 E:75 ||| NNP
for  ||| S:75 E:79 ||| IN
Chronic  ||| S:79 E:87 ||| NNP
Obstructive  ||| S:87 E:99 ||| NNP
Lung  ||| S:99 E:104 ||| NNP
Disease  ||| S:104 E:112 ||| NNP
( ||| S:112 E:113 ||| -LRB-
GOLD ||| S:113 E:117 ||| NNP
)  ||| S:117 E:119 ||| -RRB-
2011  ||| S:119 E:124 ||| CD
introduced  ||| S:124 E:135 ||| VBD
a  ||| S:135 E:137 ||| DT
new  ||| S:137 E:141 ||| JJ
multidimensional  ||| S:141 E:158 ||| JJ
system  ||| S:158 E:165 ||| NN
( ||| S:165 E:166 ||| -LRB-
symptom ||| S:166 E:173 ||| CD
/ ||| S:173 E:174 ||| CD
risk ||| S:174 E:178 ||| NN
)  ||| S:178 E:180 ||| -RRB-
for  ||| S:180 E:184 ||| IN
assessment  ||| S:184 E:195 ||| FW
chronic  ||| S:195 E:203 ||| FW
obstructive  ||| S:203 E:215 ||| FW
pulmonary  ||| S:215 E:225 ||| FW
disease  ||| S:225 E:233 ||| FW
( ||| S:233 E:234 ||| -LRB-
COPD ||| S:234 E:238 ||| NNP
) ||| S:238 E:239 ||| -RRB-
.  ||| S:239 E:241 ||| .
The  ||| S:241 E:245 ||| DT
aim  ||| S:245 E:249 ||| NN
of  ||| S:249 E:252 ||| IN
this  ||| S:252 E:257 ||| DT
study  ||| S:257 E:263 ||| NN
was  ||| S:263 E:267 ||| VBD
to  ||| S:267 E:270 ||| TO
explore  ||| S:270 E:278 ||| VB
the  ||| S:278 E:282 ||| DT
construct  ||| S:282 E:292 ||| JJ
validity  ||| S:292 E:301 ||| NN
of  ||| S:301 E:304 ||| IN
the  ||| S:304 E:308 ||| DT
GOLD  ||| S:308 E:313 ||| NNP
2011  ||| S:313 E:318 ||| CD
classification  ||| S:318 E:333 ||| JJ
strategy ||| S:333 E:341 ||| NN
;  ||| S:341 E:343 ||| :
specifically ||| S:343 E:355 ||| RB
,  ||| S:355 E:357 ||| ,
we  ||| S:357 E:360 ||| PRP
evaluated  ||| S:360 E:370 ||| VBD
its  ||| S:370 E:374 ||| PRP$
internal  ||| S:374 E:383 ||| JJ
structure  ||| S:383 E:393 ||| NN
in  ||| S:393 E:396 ||| IN
terms  ||| S:396 E:402 ||| NNS
of  ||| S:402 E:405 ||| IN
reliability  ||| S:405 E:417 ||| NN
and  ||| S:417 E:421 ||| CC
exploratory  ||| S:421 E:433 ||| JJ
factor  ||| S:433 E:440 ||| NN
analysis  ||| S:440 E:449 ||| NN
( ||| S:449 E:450 ||| -LRB-
EFA ||| S:450 E:453 ||| NNP
) ||| S:453 E:454 ||| -RRB-
.  ||| S:454 E:456 ||| .
Reliability  ||| S:456 E:468 ||| NNP
( ||| S:468 E:469 ||| -LRB-
Cronbach  ||| S:469 E:478 ||| FW
alpha  ||| S:478 E:484 ||| FW
coefficient ||| S:484 E:495 ||| FW
) ||| S:495 E:496 ||| -RRB-
,  ||| S:496 E:498 ||| ,
correlations  ||| S:498 E:511 ||| VBG
between  ||| S:511 E:519 ||| IN
variables  ||| S:519 E:529 ||| NNS
and  ||| S:529 E:533 ||| CC
two  ||| S:533 E:537 ||| CD
successive  ||| S:537 E:548 ||| JJ
EFA  ||| S:548 E:552 ||| NNP
were  ||| S:552 E:557 ||| VBD
performed  ||| S:557 E:567 ||| VBN
to  ||| S:567 E:570 ||| TO
assess  ||| S:570 E:577 ||| VB
the  ||| S:577 E:581 ||| DT
internal  ||| S:581 E:590 ||| JJ
structure  ||| S:590 E:600 ||| NN
of  ||| S:600 E:603 ||| IN
GOLD  ||| S:603 E:608 ||| NNP
2011 ||| S:608 E:612 ||| CD
.  ||| S:612 E:614 ||| .
Symptoms  ||| S:614 E:623 ||| NNS
( ||| S:623 E:624 ||| -LRB-
mMRC  ||| S:624 E:629 ||| JJ
dyspnea  ||| S:629 E:637 ||| JJ
score ||| S:637 E:642 ||| NN
)  ||| S:642 E:644 ||| -RRB-
and  ||| S:644 E:648 ||| CC
risk  ||| S:648 E:653 ||| NN
( ||| S:653 E:654 ||| -LRB-
number  ||| S:654 E:661 ||| NN
of  ||| S:661 E:664 ||| IN
previous  ||| S:664 E:673 ||| JJ
year  ||| S:673 E:678 ||| NN
exacerbations  ||| S:678 E:692 ||| NNS
and  ||| S:692 E:696 ||| CC
forced  ||| S:696 E:703 ||| VBN
expiratory  ||| S:703 E:714 ||| JJ
volume  ||| S:714 E:721 ||| NN
in  ||| S:721 E:724 ||| IN
the  ||| S:724 E:728 ||| DT
first  ||| S:728 E:734 ||| JJ
second  ||| S:734 E:741 ||| JJ
%  ||| S:741 E:743 ||| NN
of  ||| S:743 E:746 ||| IN
predicted ||| S:746 E:755 ||| CD
)  ||| S:755 E:757 ||| -RRB-
were  ||| S:757 E:762 ||| VBD
selected  ||| S:762 E:771 ||| VBN
as  ||| S:771 E:774 ||| IN
variables ||| S:774 E:783 ||| NNS
.  ||| S:783 E:785 ||| .
The  ||| S:785 E:789 ||| DT
analysis  ||| S:789 E:798 ||| NN
included  ||| S:798 E:807 ||| VBD
679  ||| S:807 E:811 ||| CD
COPD  ||| S:811 E:816 ||| NN
patients  ||| S:816 E:825 ||| NNS
from  ||| S:825 E:830 ||| IN
two  ||| S:830 E:834 ||| CD
Spanish  ||| S:834 E:842 ||| JJ
cohorts  ||| S:842 E:850 ||| NNS
( ||| S:850 E:851 ||| -LRB-
71.4 ± 11.7  ||| S:851 E:863 ||| CD
years ||| S:863 E:868 ||| NNS
) ||| S:868 E:869 ||| -RRB-
.  ||| S:869 E:871 ||| .
Alpha  ||| S:871 E:877 ||| JJ
coefficient  ||| S:877 E:889 ||| NN
of  ||| S:889 E:892 ||| IN
the  ||| S:892 E:896 ||| DT
3  ||| S:896 E:898 ||| CD
items  ||| S:898 E:904 ||| NNS
was  ||| S:904 E:908 ||| VBD
0.52  ||| S:908 E:913 ||| CD
for  ||| S:913 E:917 ||| IN
the  ||| S:917 E:921 ||| DT
whole  ||| S:921 E:927 ||| JJ
sample ||| S:927 E:933 ||| NN
.  ||| S:933 E:935 ||| .
Variables  ||| S:935 E:945 ||| NNS
presented  ||| S:945 E:955 ||| VBD
statistically  ||| S:955 E:969 ||| RB
significant  ||| S:969 E:981 ||| JJ
correlations ||| S:981 E:993 ||| NN
,  ||| S:993 E:995 ||| ,
but  ||| S:995 E:999 ||| CC
of  ||| S:999 E:1002 ||| IN
low  ||| S:1002 E:1006 ||| JJ
to  ||| S:1006 E:1009 ||| TO
moderate  ||| S:1009 E:1018 ||| JJ
magnitude ||| S:1018 E:1027 ||| NN
.  ||| S:1027 E:1029 ||| .
A  ||| S:1029 E:1031 ||| DT
first  ||| S:1031 E:1037 ||| JJ
EFA  ||| S:1037 E:1041 ||| NNP
extracted  ||| S:1041 E:1051 ||| VBD
only  ||| S:1051 E:1056 ||| RB
one  ||| S:1056 E:1060 ||| CD
factor  ||| S:1060 E:1067 ||| NN
accounting  ||| S:1067 E:1078 ||| NN
52 ||| S:1078 E:1080 ||| CD
%  ||| S:1080 E:1082 ||| NN
of  ||| S:1082 E:1085 ||| IN
the  ||| S:1085 E:1089 ||| DT
total  ||| S:1089 E:1095 ||| JJ
variance ||| S:1095 E:1103 ||| NN
.  ||| S:1103 E:1105 ||| .
A  ||| S:1105 E:1107 ||| DT
second  ||| S:1107 E:1114 ||| JJ
EFA  ||| S:1114 E:1118 ||| NNS
including  ||| S:1118 E:1128 ||| VBG
four  ||| S:1128 E:1133 ||| CD
items  ||| S:1133 E:1139 ||| NNS
( ||| S:1139 E:1140 ||| -LRB-
the  ||| S:1140 E:1144 ||| DT
three  ||| S:1144 E:1150 ||| CD
GOLD  ||| S:1150 E:1155 ||| CD
2011  ||| S:1155 E:1160 ||| CD
variables  ||| S:1160 E:1170 ||| NNS
plus  ||| S:1170 E:1175 ||| CC
comorbidities  ||| S:1175 E:1189 ||| NN
as  ||| S:1189 E:1192 ||| IN
Charlson  ||| S:1192 E:1201 ||| NNP
index  ||| S:1201 E:1207 ||| NN
score ||| S:1207 E:1212 ||| NN
) ||| S:1212 E:1213 ||| -RRB-
,  ||| S:1213 E:1215 ||| ,
extracted  ||| S:1215 E:1225 ||| VBD
two-factors  ||| S:1225 E:1237 ||| JJ
accounting  ||| S:1237 E:1248 ||| NN
for  ||| S:1248 E:1252 ||| IN
65 ||| S:1252 E:1254 ||| CD
%  ||| S:1254 E:1256 ||| NN
of  ||| S:1256 E:1259 ||| IN
the  ||| S:1259 E:1263 ||| DT
total  ||| S:1263 E:1269 ||| JJ
variance ||| S:1269 E:1277 ||| NN
.  ||| S:1277 E:1279 ||| .
The  ||| S:1279 E:1283 ||| DT
first  ||| S:1283 E:1289 ||| JJ
factor  ||| S:1289 E:1296 ||| NN
included  ||| S:1296 E:1305 ||| VBD
the  ||| S:1305 E:1309 ||| DT
three  ||| S:1309 E:1315 ||| CD
items  ||| S:1315 E:1321 ||| NNS
of  ||| S:1321 E:1324 ||| IN
GOLD  ||| S:1324 E:1329 ||| NNP
2011 ||| S:1329 E:1333 ||| CD
,  ||| S:1333 E:1335 ||| ,
and  ||| S:1335 E:1339 ||| CC
the  ||| S:1339 E:1343 ||| DT
second  ||| S:1343 E:1350 ||| NN
contained  ||| S:1350 E:1360 ||| VBD
only  ||| S:1360 E:1365 ||| RB
one  ||| S:1365 E:1369 ||| CD
variable  ||| S:1369 E:1378 ||| NNS
( ||| S:1378 E:1379 ||| -LRB-
comorbidities ||| S:1379 E:1392 ||| LS
) ||| S:1392 E:1393 ||| -RRB-
.  ||| S:1393 E:1395 ||| .
This  ||| S:1395 E:1400 ||| DT
solution  ||| S:1400 E:1409 ||| NN
was  ||| S:1409 E:1413 ||| VBD
stable  ||| S:1413 E:1420 ||| JJ
in  ||| S:1420 E:1423 ||| IN
patients  ||| S:1423 E:1432 ||| NNS
with  ||| S:1432 E:1437 ||| IN
different  ||| S:1437 E:1447 ||| JJ
levels  ||| S:1447 E:1454 ||| NNS
of  ||| S:1454 E:1457 ||| IN
COPD  ||| S:1457 E:1462 ||| NNP
severity ||| S:1462 E:1470 ||| NN
.  ||| S:1470 E:1472 ||| .
The  ||| S:1472 E:1476 ||| DT
available  ||| S:1476 E:1486 ||| JJ
evidence  ||| S:1486 E:1495 ||| NN
suggests  ||| S:1495 E:1504 ||| VBZ
that  ||| S:1504 E:1509 ||| IN
GOLD  ||| S:1509 E:1514 ||| NNP
2011  ||| S:1514 E:1519 ||| CD
strategy  ||| S:1519 E:1528 ||| NN
presented  ||| S:1528 E:1538 ||| VBD
a  ||| S:1538 E:1540 ||| DT
low  ||| S:1540 E:1544 ||| JJ
reliability ||| S:1544 E:1555 ||| NN
,  ||| S:1555 E:1557 ||| ,
and  ||| S:1557 E:1561 ||| CC
its  ||| S:1561 E:1565 ||| PRP$
theorized  ||| S:1565 E:1575 ||| JJ
multidimensionality  ||| S:1575 E:1595 ||| NN
was  ||| S:1595 E:1599 ||| VBD
not  ||| S:1599 E:1603 ||| RB
confirm  ||| S:1603 E:1611 ||| VB
by  ||| S:1611 E:1614 ||| IN
EFA ||| S:1614 E:1617 ||| NNP
.  ||| S:1617 E:1619 ||| .
Comorbidities  ||| S:1619 E:1633 ||| NNP
appears  ||| S:1633 E:1641 ||| VBZ
as  ||| S:1641 E:1644 ||| IN
a  ||| S:1644 E:1646 ||| DT
separate  ||| S:1646 E:1655 ||| JJ
and  ||| S:1655 E:1659 ||| CC
independent  ||| S:1659 E:1671 ||| JJ
domain ||| S:1671 E:1677 ||| NN
.  ||| S:1677 E:1679 ||| .
